Replies to post #26427 on Ariad Pharmaceuticals Inc fka ARIA

[bellweather1]

relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.

http://www.nejm.org/doi/full/10.1056/NEJMoa044238

113 is effective against this second mutation, so, assuming we can get to sufficient concentration (because we are somewhat less potent to EGFR), we've got this one licked!

Thanks for the link.

[bellweather1]

Feb 24, 2005-

Didn't initially realize how ancient this article was.

Nevertheless, instructive concerning part of the EGFR challenge Ariad was aware of, in designing 113.